Quintis CEO Succession
The Board of Quintis is pleased to announce that Richard Henfrey has been appointed to succeed Julius Matthys as Chief Executive Officer of the Company. Mr Matthys will remain with the Company as a Non-Executive Director.
The Board of Quintis is pleased to announce that Richard Henfrey has been appointed to succeed Julius Matthys as Chief Executive Officer of the Company. Mr Matthys will remain with the Company as a Non-Executive Director.
Read moreA newly recapitalised Quintis (“Company”) has today emerged from receivership after receiving A$145 million in funding from its new owners, including funds and accounts under management by BlackRock Advisors, LLC and its affiliates.
Read moreOur 2018 harvest season has now come to an end. Over the last few months our specialised harvest team successfully harvested approximately 13,600 Indian sandalwood trees on behalf of Quintis, an institutional investor and retail investors.
Read moreSantalis Pharmaceuticals Enrolls First U.S. Subject Into a Ph2 Clinical Study of Mild to Moderate Atopic Dermatitis (Eczema).
Read moreSantalis Pharmaceuticals announced the granting by the Australian Patent Office of Patent No. 2011223758 containing 16 claims covering the use of Sandalwood oil compositions to treat a variety of cancers including Leukemia and solid tumors such as bladder cancer and others.
Read moreQuintis Queensland Indian Sandalwood plantations largely unaffected by Cyclone Debbie
Read moreIn a global study of the Indian sandalwood industry, a leading management consultancy firm estimated that China will consume around 40% of all legal and authentic Indian sandalwood by 2025.
Read moreIn March 2017 TFS will rebrand to Quintis.
Read more